<DOC>
	<DOCNO>NCT02112578</DOCNO>
	<brief_summary>- Evaluation non inferiority Meclin ( meclizine ) versus Dramin ( Dimenhydrinate ) treat symptom acute vertigo peripheral origin 4 week treatment ; - Evaluation impact quality life vertigo ; - Compare intensity daytime sleepiness two treatment group ; - Compare efficacy drug relieve 10 symptom make VS ; - Compare duration treatment treatment group ; - Compare Adehence ; - Compare level satisfaction group investigator subject ; - Adverse event ;</brief_summary>
	<brief_title>Non Inferiority Meclin® ( Meclizine Chlorhydrate ) Versus Dramin® ( Dimenhydrinate ) Control Acute Vertigo Symptoms From Peripheral Origin</brief_title>
	<detailed_description>It prospective interventional study arm parallel , active -controlled , non-inferiority . Participants select study sex , age 18 year less 65 , meet inclusion criterion fit exclusion criterion , agree purpose study . Participants divide two accord randomization treatment group 1:1 . The study take long 30 day complete amount 6 visit ( 7±2 day ) : V0 radomization ; V1 , V2 , V3 andV4 ( FV ) Evaluation visit One Follow visit 7±2 day Final Visit .</detailed_description>
	<mesh_term>Vertigo</mesh_term>
	<mesh_term>Dizziness</mesh_term>
	<mesh_term>Dimenhydrinate</mesh_term>
	<mesh_term>Meclizine</mesh_term>
	<criteria>Men woman age 18 year less 65 ; Presence vertigo episodes vestibular origin ( peripheral ) moderate intensity , strong strong accord VS range ; Participants able swallow tablet / capsule ; Participants able understand guidance care study cooperative ; Participants requisite understanding , accordance Good Clinical Practice Research Document Americas . Use meclizine dimenidrynate actual event past 15 day ; Use alcohol past 48 hour ; Presence vomit prevent ingestion tablet ; Pregnancy breastfeeding ; Presence clinical condition determines contraindication active substance : convulsion , suspect intracranial compressive process , closedangle glaucoma , prostatic adenoma urinary disorder , liver disease , endocrine , renal , / uncontrolled cardiovascular , Parkinson 's disease , porphyria , know history hipersensibility Actives Excipients study medication ; Malignancies History , even evidence active disease less five year . Those without active disease five year may include ; Uncontrolled systemic arterial hypertension ( &gt; 140/90 mmHg ) ; Decompensated diabetes mellitus ( blood glucose time &gt; 200 mg / dL ) ; Participants asthma chronic obstructive pulmonary disease ; Participants make use antihistamine antivertigo effect ( betahistine , meclizine , diphenidol ) , drug antagonist calcium channel action ( cinnarizine , flunarizine ) , anticholinergic drug ( metoclopramide , dimenhydrinate , meclizine , diphenidol , scopolamine , ondansetron , granisetron ) , antiseizure drug ( diazepam , clonazepam , carbamazepine ) central nervous system depressant ; Participants central origin vertigo nonvestibular ; Participants positional benign positional paroxysmal vertigo ( bppv ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Vertigo , Meclizine , dimenhydrinate , Peripheral Origin</keyword>
</DOC>